Economic burden of antibiotic resistance: how much do we really know?

The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.

[1]  R B Roberts,et al.  Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[3]  Y. Tabak,et al.  Surgical site infections: Causative pathogens and associated outcomes. , 2010, American journal of infection control.

[4]  C. Price,et al.  Epidemiologic, Clinical, and Economic Evaluation of an Outbreak of Clonal Multidrug-Resistant Acinetobacter baumannii Infection in a Surgical Intensive Care Unit , 2007, Infection Control & Hospital Epidemiology.

[5]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Mertens,et al.  Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. , 2011, The Lancet. Infectious diseases.

[7]  A. Shorr.  Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus , 2012, PharmacoEconomics.

[8]  Laura A. Conn,et al.  Trends in Infectious Disease Mortality in the United States During the 20th Century , 1999 .

[9]  T. Perl,et al.  Effect of Nosocomial Vancomycin-Resistant Enterococcal Bacteremia on Mortality, Length of Stay, and Costs , 2003, Infection Control & Hospital Epidemiology.

[10]  L. Mermel,et al.  Are There Differences in Hospital Cost Between Patients With Nosocomial Methicillin-Resistant Staphylococcus aureus Bloodstream Infection and Those With Methicillin-Susceptible S. aureus Bloodstream Infection? , 2009, Infection Control & Hospital Epidemiology.

[11]  I. Rudan,et al.  Aetiology of community-acquired neonatal sepsis in low and middle income countries , 2011, Journal of global health.

[12]  J. Decruyenaere,et al.  COSTS AND LENGTH OF STAY ASSOCIATED WITH ANTIMICROBIAL RESISTANCE IN ACUTE KIDNEY INJURY PATIENTS WITH BLOODSTREAM INFECTION , 2008, Acta clinica Belgica.

[13]  M. Bonten,et al.  Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[14]  C. van Delden,et al.  Multidrug Resistant Gram‐Negative Bacteria in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  J. Schrenzel,et al.  Burden of Bloodstream Infection Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Determined Using Multistate Modeling at a Swiss University Hospital and a Nationwide Predictive Model , 2013, Infection Control & Hospital Epidemiology.

[16]  Martin Schumacher,et al.  The impact of time‐dependent bias in proportional hazards modelling , 2008, Statistics in medicine.

[17]  E. Khan,et al.  Increased isolation of ESBL producing Klebsiella pneumoniae with emergence of carbapenem resistant isolates in Pakistan: report from a tertiary care hospital. , 2010, JPMA. The Journal of the Pakistan Medical Association.

[18]  S. Mshana,et al.  Open Access Research Article Predictors of Positive Blood Culture and Deaths among Neonates with Suspected Neonatal Sepsis in a Tertiary Hospital, Mwanza-tanzania , 2022 .

[19]  T. Spanu,et al.  Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles. , 2012, Transplantation proceedings.

[20]  S. Cosgrove,et al.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Mark J. Thomas,et al.  Consequences of vancomycin‐resistant Enterococcus in liver transplant recipients: a matched control study , 2005, Clinical transplantation.

[22]  S. Cosgrove,et al.  The impact of antimicrobial resistance on health and economic outcomes. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  H. Evans,et al.  Cost of Gram‐negative resistance* , 2007, Critical care medicine.

[24]  A V Swan,et al.  The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. , 2001, The Journal of hospital infection.

[25]  Gopi Patel,et al.  Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies , 2008, Infection Control & Hospital Epidemiology.

[26]  N. Bansback,et al.  Measuring and valuing productivity loss due to poor health: A critical review. , 2011, Social science & medicine.

[27]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control & Hospital Epidemiology.

[28]  E. Larson,et al.  Factors Associated With Variation in Estimates of the Cost of Resistant Infections , 2010, Medical care.

[29]  Herman Goossens,et al.  Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action , 2012, Antimicrobial Resistance and Infection Control.

[30]  S. Dasgupta,et al.  Profile of Neonatal Septicaemia at a District-level Sick Newborn Care Unit , 2012, Journal of health, population, and nutrition.

[31]  L. Riley,et al.  Risk Factors and Costs Associated With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections , 2004, Infection Control & Hospital Epidemiology.

[32]  D. Nicolau,et al.  Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. , 2014, Journal of hospital medicine.

[33]  I. Oh,et al.  Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores , 2011, Infection.

[34]  G. Oster,et al.  Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. , 2010, Journal of hospital medicine.

[35]  D. De Bacquer,et al.  Measuring the impact of multidrug resistance in nosocomial infection , 2007, Current opinion in infectious diseases.

[36]  Jessina C. McGregor,et al.  Controlling for Severity of Illness in Outcome Studies Involving Infectious Diseases: Impact of Measurement at Different Time Points , 2008, Infection Control & Hospital Epidemiology.

[37]  L. Zhong,et al.  Prevalence of multidrug‐resistant gram‐negative bacilli producing extended‐spectrum β‐lactamases (ESBLs) and ESBL genes in solid organ transplant recipients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[38]  K. Garey,et al.  Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. , 2006, Clinical therapeutics.

[39]  Martin Schumacher,et al.  An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. , 2008, Journal of clinical epidemiology.

[40]  J. Coast,et al.  Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. , 2005, Journal of health economics.

[41]  Hajo Grundmann,et al.  Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe , 2011, PLoS medicine.

[42]  Peter Davey,et al.  Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. , 2011, The Journal of antimicrobial chemotherapy.

[43]  K. Sepkowitz,et al.  Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia , 2002, Infection Control & Hospital Epidemiology.

[44]  G. Wormser,et al.  Costs and Savings Associated With Infection Control Measures That Reduced Transmission of Vancomycin-Resistant Enterococci in an Endemic Setting , 2001, Infection Control & Hospital Epidemiology.

[45]  D. Livermore,et al.  Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. , 2014, The Journal of infection.

[46]  M. Schumacher,et al.  Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. , 2000, Journal of clinical epidemiology.

[47]  Richard Smith,et al.  The true cost of antimicrobial resistance , 2013, BMJ.

[48]  G. Fadda,et al.  Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy , 2010, Antimicrobial Agents and Chemotherapy.

[49]  Yehuda Carmeli,et al.  Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2006, Antimicrobial Agents and Chemotherapy.

[50]  S. Cosgrove.  The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  D. Sexton,et al.  Nosocomial Methicillin-Resistant and Methicillin-Susceptible Staphylococcus Aureus Primary Bacteremia: At What Costs? , 1999, Infection Control & Hospital Epidemiology.

[52]  Y. Carmeli,et al.  Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.

[53]  M. Sharland,et al.  Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries. , 2015, Journal of the Pediatric Infectious Diseases Society.

[54]  S. Jayachandran,et al.  Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs , 2010 .

[55]  W. Ko,et al.  Clinical and Economic Impact of Multidrug Resistance in Nosocomial Acinetobacter baumannii Bacteremia , 2007, Infection Control & Hospital Epidemiology.

[56]  Bala Hota,et al.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  K. Manji,et al.  High Rate of Fatal Cases of Pediatric Septicemia Caused by Gram-Negative Bacteria with Extended-Spectrum Beta-Lactamases in Dar es Salaam, Tanzania , 2005, Journal of Clinical Microbiology.

[58]  M. Synnestvedt,et al.  Imipenem Resistance in Pseudomonas aeruginosa Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes , 2010, Infection Control & Hospital Epidemiology.

[59]  P. Davey,et al.  Clinical Impact of Antimicrobial Resistance in European Hospitals: Excess Mortality and Length of Hospital Stay Related to Methicillin-Resistant Staphylococcus aureus Bloodstream Infections , 2011, Antimicrobial Agents and Chemotherapy.

[60]  Benjamin A Lipsky,et al.  Skin, Soft Tissue, Bone, and Joint Infections in Hospitalized Patients: Epidemiology and Microbiological, Clinical, and Economic Outcomes , 2007, Infection Control & Hospital Epidemiology.

[61]  P. Davey,et al.  Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. , 2011, The Journal of antimicrobial chemotherapy.

[62]  F. Schwab,et al.  Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus. , 2010, The Journal of hospital infection.

[63]  S. Solomon,et al.  Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  M. Postelnick,et al.  Enterococcus faecium bacteremia: does vancomycin resistance make a difference? , 1998, Archives of internal medicine.

[65]  L. Bockstedt,et al.  Excess Costs and Utilization Associated with Methicillin Resistance for Patients with Staphylococcus aureus Infection , 2010, Infection Control & Hospital Epidemiology.

[66]  Y. Carmeli,et al.  Health and economic outcomes of vancomycin-resistant enterococci. , 2002, Archives of internal medicine.

[67]  J. Cruzado,et al.  Risk Factors and Outcomes of Bacteremia Caused by Drug-Resistant ESKAPE Pathogens in Solid-Organ Transplant Recipients , 2013, Transplantation.

[68]  E. Perencevich,et al.  Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. , 2010, Archives of internal medicine.

[69]  E. Larson,et al.  Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  R. Rubin,et al.  The economic impact of Staphylococcus aureus infection in New York City hospitals. , 1999, Emerging infectious diseases.

[71]  E. Armstrong,et al.  Clinical and Economic Analysis of Methicillin-Susceptible and -Resistant Staphylococcus aureus Infections , 2004, The Annals of pharmacotherapy.

[72]  S. Cosgrove,et al.  Clinical and economic burden of antimicrobial resistance , 2008, Expert review of anti-infective therapy.

[73]  N. Powe,et al.  Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes , 2002, Intensive Care Medicine.

[74]  J. Coast,et al.  A macroeconomic approach to evaluating policies to contain antimicrobial resistance , 2006, Applied health economics and health policy.

[75]  J. Beyersmann,et al.  Estimating the impact of healthcare-associated infections on length of stay and costs. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[76]  Nicholas Graves,et al.  The time-dependent bias and its effect on extra length of stay due to nosocomial infection. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[77]  Y. Tabak,et al.  Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia , 2006, Critical care.

[78]  Brad Spellberg,et al.  Combating antimicrobial resistance: policy recommendations to save lives. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  L. Martínez-Martínez,et al.  Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[80]  M. Synnestvedt,et al.  Epidemiology and Impact of Imipenem Resistance in Acinetobacter baumannii , 2009, Infection Control & Hospital Epidemiology.

[81]  K. Anstrom,et al.  Costs and Outcomes Among Hemodialysis-Dependent Patients With Methicillin-Resistant or Methicillin-Susceptible Staphylococcus aureus Bacteremia , 2005, Infection Control & Hospital Epidemiology.

[82]  R. Sood,et al.  Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. , 2004, American journal of infection control.

[83]  T. Lodise,et al.  Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. , 2005, Diagnostic microbiology and infectious disease.

[84]  J. Schrenzel,et al.  Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. , 2013, The Journal of hospital infection.